1. Why Training is the Key to Successful Guideline Implementation

   • A. David Paltiel
   • Peter J. Neumann

   Current Opinion 15 November 2012 Pages: 297 - 302

2. The Economic Potential of Tamoxifen Prophylaxis in Breast Cancer

   • James R. G. Butler

   Current Opinion 15 November 2012 Pages: 303 - 306

3. Strategies to Improve the Cost Effectiveness of General Practitioner Prescribing

   • Hugh McGavock

   Leading Article 15 November 2012 Pages: 307 - 311

4. The US Orphan Drug Programme

   • Sheila R. Shulman
   • Michael Manocchia

   Review Article 15 November 2012 Pages: 312 - 326

5. Economics of Home Parenteral Nutrition

   • Alan Cade
   • John Puntis

   Review Article 15 November 2012 Pages: 327 - 338

6. Drug Rationing in the UK National Health Service

   • Tom Walley
   • Alan Haycox
   • Stuart Barton

   Review Article 15 November 2012 Pages: 339 - 350

7. Treatment Costs and Quality of Life with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Antineoplastic Therapy—Related Febrile Neutropenia

   • Carin A. Uyl-de Groot
   • Edo Vellenga
   • Frans F. H. Rutten

   Original Research Article 15 November 2012 Pages: 351 - 360

8. Cost Effectiveness of Hepatitis A Virus Immunisation in Spain

   • José M. Arnal
   • Olga Frisas
   • Fernando Antoñanzas

   Original Research Article 15 November 2012 Pages: 361 - 373

9. Cost-Effective Treatment of Uncomplicated Gonorrhoea Including Co-Infection with Chlamydia trachomatis

   • Mehmet Genç
   • Per-Anders Mårdh

   Original Research Article 15 November 2012 Pages: 374 - 383

10. A Predictive Model of the Health Benefits and Cost Effectiveness of Celiprolol and Atenolol in Primary Prevention of Cardiovascular Disease in Hypertensive Patients

    • Richard J. Milne
    • Stephen Vander Hoorn
    • Rodney T. Jackson

    Original Research Article 15 November 2012 Pages: 384 - 408

11. Dornase Alfa

    • Karen L. Goa
    • Harriet Lamb

    Adis Pharmacoeconomic Drug Evaluation 15 November 2012 Pages: 409 - 422